Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/10/13Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune today announces the release of interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. The study Chair presented these updated results today at the annual meeting of the American Society of Hematology (ASH). Please click on the link below to download the full Press Release:- Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigen... 
Printer Friendly Version
11/20/13Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board
Adaptimmune today announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman of the company since foundation and will remain on the Board as Deputy Chairman. Please click on the link below to download the full Press Release:- Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board... 
Printer Friendly Version
07/25/13Adaptimmune Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif. Researchers will investigate the safety, bioactivity and effectiveness of treating patients with their own T cells after genetically engineering the cells to enhance their antitumor properties. Click on here to download full Press Release... 
Printer Friendly Version
01/16/13Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy
NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune’s clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT0135228... 
Printer Friendly Version